Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis

Journal of Proteome Research

Volumn 9, Issue 1, 2010, Pages 216-226

  Pang, Jun ^a   Liu, Wei Peng ^a   Liu, Xiao Peng ^a   Li, Liao Yuan ^a   Fang, You Qiang ^a   Sun, Qi Peng ^a   Liu, Shao Jun ^b   Li, Ming Tao ^b   Su, Zu Lan ^a   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biomarker; Lymph node metastasis; Prostate cancer; Proteomics

Indexed keywords

EZRIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; INORGANIC PYROPHOSPHATASE; METHYLCROTONOYL COENZYME A CARBOXYLASE; STOMATIN; STOMATIN LIKE PROTEIN 2; TRANSGELIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FATTY ACID-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 73649114942     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900953s     Document Type: Article

References (43)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y. P.; Xu, J. Q.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA. Cancer J. Clin. 2008, 58, 71-96.
2. Miyake, H.; Hara, I.; Kurahashi, T.; Inoue, T. A.; Eto, H.; Fujisawa, M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by realtime reverse transcriptase-PCR. Clin. Cancer Res. 2007, 13, 1192-1197.
3. Swanson, G. P.; Thompson, I. M.; Basler, J. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 2006, 107, 439-450.
4. Weckermann, D.; Dorn, R.; Trefz, M.; Wagner, T.; Wawroschek, F.; Harzmann, R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J. Urol. 2007, 177, 916-920.
5. Sivalingam, S.; Oxley, J.; Probert, J. L.; Stolzenburg, J. U.; Schwaibold, H. Role of pelvic lymphadenectomy in prostate cancer management. Urology 2007, 69, 203-209.
6. Martinez-Pineiro, L.; Rios, E.; Martinez-Gomariz, M.; Pastor, T.; de Cabo, M.; Picazo, M. L.; Palacios, J.; Perona, R. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur. Urol. 2003, 43, 342-350.
7. Jeschke, S.; Nambirajan, T.; Leeb, K.; Ziegerhofer, J.; Sega, W.; Janetschek, G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J. Urol. 2005, 173, 1943-1946.
8. Bradford, T. J.; Tomlins, S. A.; Wang, X.; Chinnaiyan, A. M. Molecular markers of prostate cancer. Urol. Oncol. 2006, 24, 538-551.
9. Mimeault, M.; Batra, S. K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006, 27, 1-22.
10. Gretzer, M. B.; Chan, D. W.; van Rootselaar, C. L.; Rosenzweig, J. M.; Dalrymple, S.; Mangold, L. A.; Partin, A. W.; Veltri, R. W. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Prostate 2004, 60, 325-331.
11. Rowland, J. G.; Robson, J. L.; Simon, W. J.; Leung, H. Y.; Slabas, A. R. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 2007, 7, 47-63.
12. Wyler, S. F.; Sulser, T.; Seifert, H. H.; Ruszat, R.; Forster, T. H.; Gasser, T. C.; Bachmann, A. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 2006, 68, 883-887.
13. Daneshmand, S.; Quek, M. L.; Stein, J. P.; Lieskovsky, G.; Cai, J.; Pinski, J.; Skinner, E. C.; Skinner, D. G. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol. 2004, 172, 2252-2255.
14. Bader, P.; Burkhard, F. C.; Markwalder, R.; Studer, U. E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure. J. Urol. 2003, 169, 849-854.
15. Paris, P. L.; Andaya, A.; Fridlyand, J.; Jain, A. N.; Weinberg, V.; Kowbel, D.; Brebner, J. H.; Simko, J.; Watson, J. E.; Volik, S.; Albertson, D. G.; Pinkel, D.; Alers, J. C.; van der Kwast, T. H.; Vissers, K. J.; Schroder, F. H.; Wildhagen, M. F.; Febbo, P. G.; Chinnaiyan, A. M.; Pienta, K. J.; Carroll, P. R.; Rubin, M. A.; Collins, C.; van Dekken, H. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet. 2004, 13, 1303-1313.
16. Jin, S.; Shen, J. N.; Guo, Q. C.; Zhou, J. G.; Wang, J.; Huang, G. 2-D DIGE and MALDI-TOF-MS analysis of the serum proteome in human osteosarcoma. Proteomics: Clin. Appl. 2007, 272-285.
17. Fu, H.; Li, W.; Liu, Y.; Lao, Y.; Liu, W.; Chen, C.; Yu, H.; Lee, N. T.; Chang, D. C.; Li, P.; Pang, Y.; Tsim, K. W.; Li, M.; Han, Y. Mitochondrial proteomic analysis and characterization of the intracellular mechanisms of bis(7)-tacrine in protecting against glutamate-induced excitotoxicity in primary cultured neurons. J. Proteome Res. 2007, 6, 2435-2446.
18. Jackson, D.; Rowlinson, R. A.; Eaton, C. K.; Nickson, J. A.; Wilson, I. D.; Mills, J. D.; Wilkinson, R. W.; Tonge, R. P. Prostatic tissue protein alterations due to delayed time to freezing. Proteomics 2006, 6, 3901-3908.
19. Relative quantitation of gene expression. In: ABI's User Bulletin No. 2. Applied Biosystems, 1997.
20. Cui, Y.; Wu, J.; Zong, M.; Song, G.; Jia, Q.; Jiang, J.; Han, J. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 2009, 124, 1614-1621.
21. Pei, H.; Zhu, H.; Zeng, S.; Li, Y.; Yang, H.; Shen, L.; Chen, J.; Zeng, L.; Fan, J.; Li, X.; Gong, Y.; Shen, H. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 2007, 6, 2495-2501.
22. Pound, C. R.; Partin, A. W.; Eisenberger, M. A.; Chan, D. W.; Pearson, J. D.; Walsh, P. C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281, 1591-1597.
23. Oyen, R. H.; Van Poppel, H. P.; Ameye, F. E.; Van de Voorde, W. A.; Baert, A. L.; Baert, L. V. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994, 190, 315-322.
24. Lessard, L.; Karakiewicz, P. I.; Bellon-Gagnon, P.; Alam-Fahmy, M.; Ismail, H. A.; Mes-Masson, A. M.; Saad, F. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin. Cancer Res. 2006, 12, 5741-5745.
25. Taylor, B. S.; Varambally, S.; Chinnaiyan, A. M. Differential proteomic alterations between localised and metastatic prostate cancer. Br. J. Cancer 2006, 95, 425-430.
26. Gorg, A.; Weiss, W.; Dunn, M. J. Current two-dimensional electrophoresis technology for Proteomics. Proteomics 2004, 4, 3665-3685.
27. Liotta, L. A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986, 46, 1-7.
28. Jing, C.; Beesley, C.; Foster, C. S.; Rudland, P. S.; Fujii, H.; Ono, T.; Chen, H.; Smith, P. H.; Ke, Y. Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res. 2000, 60, 2390-2398.
29. Morgan, E. A.; Forootan, S. S.; Adamson, J.; Foster, C. S.; Fujii, H.; Igarashi, M.; Beesley, C.; Smith, P. H.; Ke, Y. Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression. Int. J. Oncol. 2008, 32, 767-775.
30. Adamson, J.; Morgan, E. A.; Beesley, C.; Mei, Y.; Foster, C. S.; Fujii, H.; Rudland, P. S.; Smith, P. H.; Ke, Y. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 2003, 22, 2739-2749.
31. Jing, C.; Beesley, C.; Foster, C. S.; Chen, H.; Rudland, P. S.; West, D. C.; Fujii, H.; Smith, P. H.; Ke, Y. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res. 2001, 61, 4357-4364.
32. Baumgartner, M. R.; Almashanu, S.; Suormala, T.; Obie, C.; Cole, R. N.; Packman, S.; Baumgartner, E. R.; Valle, D. The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J. Clin. Invest. 2001, 107, 495-504.
33. Tomonaga, T.; Matsushita, K.; Yamaguchi, S.; Oh-Ishi, M.; Kodera, Y.; Maeda, T.; Shimada, H.; Ochiai, T.; Nomura, F. Identification of Altered Protein Expression and Post-Translational Modifications in Primary Colorectal Cancer by Using Agarose Two-Dimensional Gel Electrophoresis. Clin. Cancer Res. 2004, 10, 2007-2014.
34. Chen, G.; Gharib, T. G.; Huang, C. C.; Thomas, D. G.; Shedden, K. A.; Taylor, J. M.; Kardia, S. L.; Misek, D. E.; Giordano, T. J.; Iannettoni, M. D.; Orringer, M. B.; Hanash, S. M.; Beer, D. G. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 2002, 8, 2298-2305.
35. Dattoli, G.; Guiot, C.; Delsanto, P. P.; Ottaviani, P. L.; Pagnutti, S.; Deisboeck, T. S. Cancer metabolism and the dynamics of metastasis. J. Theor. Biol. 2009, 256, 305-310.
36. Cui, Z.; Zhang, L.; Hua, Z.; Cao, W.; Feng, W.; Liu, Z. Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol. Rep. 2007, 17, 829-833.
37. Zhang, L.; Ding, F.; Cao, W.; Liu, Z.; Liu, W.; Yu, Z.; Wu, Y.; Li, W.; Li, Y.; Liu, Z. Stomatin-like Protein 2 Is Overexpressed in Cancer and Involved in Regulating Cell Growth and Cell Adhesion in Human Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. 2006, 12, 1639-1646.
38. Yu, Y.; Khan, J.; Khanna, C.; Helman, L.; Meltzer, P. S.; Merlino, G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 2004, 10, 175-181.
39. Curto, M.; McClatchey, A. I. Ezrin: a metastatic detERMinant. Cancer Cell 2004, 5, 113-114.
40. Elliott, B. E.; Meens, J. A.; SenGupta, S. K.; Louvard, D.; Arpin, M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005, 7, 365-373.
41. Hunter, K. W. Ezrin, a key component in tumor metastasis. Trends. Mol. Med. 2004, 10, 201-204.
42. Chuan, Y. C.; Pang, S. T.; Cedazo-Minguez, A.; Norstedt, G.; Pousette, A.; Flores-Morales, A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J. Biol. Chem. 2006, 281, 29938-29948.
43. Wong, Y. C.; Tam, N. N. Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 2002, 70, 633-645.